Article in Science immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Vadim A KlenchinDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0009-0009-8442-1278
Natasha M ClarkDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-3152-892X
Nida K KelesDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.
Saverio CapuanoWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0003-2505-9124
Rosemarie MasonVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7123-4902
Guangping GaoDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01605, USA.ORCID 0000-0003-0097-9012
Aimee BromanDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0003-3783-2807
Emek KoseAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Taina T ImmonenAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0003-4521-0696
Christine M FennesseyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-8736-8523
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-2381-1151
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-9494-0268
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7448-7040
Matthew R GardnerDivision of Infectious Diseases, Department of Medicine, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0003-2872-7597
David T EvansDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0003-2498-6292
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque modelR01AI167732 · NIAID · UNIVERSITY OF FLORIDA · PI David T Evans, Susana T Valente · 2021 to 2026
$4.3M
Assessing ADCC and Fc-mediated Protection against HIVR01AI148379 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T, FINZI, ANDRES · 2019 to 2023
$3.8M
Harnessing adaptive NK cell transfer to deplete viral reservoirsR01AI161816 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BARKER, EDWARD, EVANS, DAVID T · 2021 to 2025
$3.8M
Tethering lentiviral restriction to Fc-mediated antibody responsesR01AI155163 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2020 to 2024
$3.2M
KIR and MHC Class I Immunogenetics in SIV InfectionR01AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.7M
Lentiviral Resistance to TetherinR01AI098485 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
An alternative to lifelong antiretroviral therapy (ART) is needed to achieve durable control of HIV-1. Here, we show that adeno-associated virus (AAV) delivery of two rhesus macaque antibodies to the simian immunodeficiency virus (SIV) envelope glycoprotein (Env) with potent neutralization and antibody-dependent cellular cytotoxicity can prevent viral rebound in macaques infected with barcoded SIV
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy. · full record | OpenQuestion